|
Letermovir tablets are used to prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received a bone marrow transplant or kidney transplant.
The drug (USRLD: Prevymis tablets), available in 240 mg and 480 mg variants, are set to be manufactured at the company's formulation manufacturing facility in Ahmedabad SEZ, India. It had annual sales of $289.5 million in the United States.
The group now has 393 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The pharmaceutical company reported 26.76% increase in consolidated net profit of Rs 789.6 crore on 5.83% rise in revenue from operations to Rs 4,343.70 crore in Q3 FY24 over Q3 FY23.
Shares of Zydus Lifesciences rose 0.79% to close at Rs 999.50 on Friday, 22nd March.
|